Removal of all radioactive sentinel nodes in breast cancer improves the detection of positive sentinel nodes
- PMID: 18558581
- DOI: 10.1007/s12094-008-0210-0
Removal of all radioactive sentinel nodes in breast cancer improves the detection of positive sentinel nodes
Abstract
Objective: The aim of this study is to evaluate if it is necessary to remove all the radioactive sentinel lymph nodes (SLNs) not seen on lymphoscintigraphy in order to accurately stage breast cancer patients.
Material and methods: From March 1999 to March 2006, SLN biopsy was performed in 461 patients. All patients were only injected with radioisotope. Lymphoscintigraphy was performed in all the patients. The mean number of SLNs removed was 2.1 (range 1-15).
Results: The SLN was positive in 133 patients (28.8%). Lymphoscintigraphy accurately predicted the number of SLNs identified intraoperatively in 243 patients (52.7%). In 175 patients (37.9%) there were more SLNs identified intraoperatively than were seen on lymphos cintigraphy. In 11 (6.2%) of these 175 patients, additional SLNs identified intraoperatively harboured metastasis. Type of injection, need for a second injection, tumour location and age were not identified as statistically significantly associated with additional positive SLNs identified intraoperatively and not seen on lymphoscintigraphy.
Conclusions: Lymphoscintigraphy does not accurately predict the number of SLNs identified intraoperatively, this number being underestimated. Surgeons should remove all radioactive SLNs to improve the detection of positive SLNs.
Similar articles
-
Correlation of lymphoscintigraphy with the number of sentinel lymph nodes identified intraoperatively in patients with breast cancer.Am J Surg. 2005 Oct;190(4):567-9. doi: 10.1016/j.amjsurg.2005.06.012. Am J Surg. 2005. PMID: 16164921
-
Preoperative lymphoscintigraphy and internal mammary sentinel lymph node biopsy do not enhance the accuracy of lymphatic mapping for breast cancer.Am Surg. 2004 Dec;70(12):1050-5; discussion 1055-6. Am Surg. 2004. PMID: 15663043
-
Dye- and gamma probe-guided sentinel lymph node biopsy in breast cancer patients: using patent blue dye and technetium-99m-labeled human serum albumin.Breast Cancer. 2000 Jan;7(1):87-94. doi: 10.1007/BF02967195. Breast Cancer. 2000. PMID: 11029778
-
Evaluation of lymph node status in male breast cancer patients: a role for sentinel lymph node biopsy.Breast Cancer Res Treat. 2003 Jan;77(1):9-14. doi: 10.1023/a:1021173902253. Breast Cancer Res Treat. 2003. PMID: 12602900
-
Intradermal radioisotope is superior to peritumoral blue dye or radioisotope in identifying breast cancer sentinel nodes.J Am Coll Surg. 2004 Oct;199(4):561-6. doi: 10.1016/j.jamcollsurg.2004.06.018. J Am Coll Surg. 2004. PMID: 15454139 Review.
References
MeSH terms
LinkOut - more resources
Medical